Systemic Lupus Erythematous SLE Drugs Market to Register Substantial Expansion by 2025


Valley Cottage, NY -- (SBWire) -- 12/20/2017 --Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud's phenomenon, livedo reticularis, thrombosis, and myositis. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening severity. It is also called as drug-induced lupus erythematosus due to common observation against drugs such as isoniazid, hydralazine and procainamide. Currently, there is no complete treatment for SLE. While only two biologic agents have been approved by FDA to treat SLE, synthetic drugs are still the mainstay of therapy in SLE. Based on available evidence, azathioprine and mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug in SLE because of the multiple beneficial effects of this agent.

Global systemic lupus erythematous drugs market growth is fast in North American region and is estimated to project remarkable CAGR growth throughout forecast period. In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans according to Centers for Disease Control and Prevention (CDC). The second largest and fastest growing global systemic lupus erythematous drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double digit CAGR due to higher prevalence of SLE in Europe. Among the European countries Sweden, Iceland, Spain had the highest prevalence according to Lupus Journal article, published in 2006. A drug called hydroxychloroquine being the last drug was approved by FDA in 1955 for SLE treatment. Recently, a drug called belimumab has been approved by FDA after 50 years long gap specifically for SLE on March 9, 2011. It is the first ever targeted biological drug for the treatment of SLE patients developed by Human Genome Sciences Inc. in collaboration with GlaxoSmithKline. It will be the primary driver for global systemic lupus erythematous drugs market growth in the US, France, Germany, Italy Spain, the UK and Japan. Benlysta will lead market sales in coming years because of its excellent safety profile as well as proven efficacy in clinical trials. NSAIDS such as Ibuprofen and aspirin are widely prescribed drugs for suppressing symptoms of SLE. Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE treatment. Additionally, the entry of four first-in-class (FIC) biologics such as Bristol-Myers Squibb's Orencia (abatacept), atacicept, epratuzumab and LY2127399 are anticipated to show a major role in the expansion of the global systemic lupus erythematous drugs market.

Request to sample report@

The global systemic lupus erythematous drugs market key players are Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

Media Relations Contact

Rahul Singh
Marketing Head

View this press release online at: